JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Click Here for 5% Off Your First Aladdin Purchase!

྾

Home
Applications
Targets
Kinases
TK:Tyrosine kinase
Bozitinib (PLB-1001) - 98%, high purity , CAS No.1440964-89-5, Inhibitor of MET proto-oncogene; receptor tyrosine kinase

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Bozitinib (PLB-1001) - 98%, high purity , CAS No.1440964-89-5, Inhibitor of MET proto-oncogene; receptor tyrosine kinase

Moligand™
≥98%

CAS#: 1440964-89-5
Formula: C₂₀H₁₅F₃N₈
Molecular Weight: 424.38
PubChem CID: 72202701

Item Number

B413622

Grouped product items
SKU	Size	Availability	Price
B413622-1mg	1mg	In stock	$163.90
B413622-5mg	5mg	In stock	$345.90
B413622-25mg	25mg	In stock	$1,088.90
B413622-50mg	50mg	In stock	$1,830.90

c-Met Inhibitors

View related series

MET proto-oncogene，receptor tyrosine kinase Inhibitor

Basic Description

Synonyms	Bozitinib\|Vebreltinib\|1440964-89-5\|PLB-1001\|APL-101\|Bozitinib (PLB-1001)\|Vebreltinib [USAN]\|CBT-101\|CBI-3103\|2WZP8A9VFN\|6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine\|1,2,4-Triazolo(4,3-b)
Specifications & Purity	98%
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Inhibitor of MET proto-oncogene; receptor tyrosine kinase
Product Description	Information Bozitinib (PLB-1001) Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models. Targets c-Met

Product Properties

ALogP	3.548
Rotatable Bond	4

Associated Targets

MET Tclin Hepatocyte growth factor receptor 0 Activities

Discover Target: MET

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
INCHI	InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
InChi Key	QHXLXUIZUCJRKV-UHFFFAOYSA-N
Canonical SMILES	CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
Isomeric SMILES	CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
PubChem CID	72202701
Molecular Weight	424.38

Database links

CAS Registry No.	1440964-89-5
PubChem CID	72202701
BindingDB Ligand	107096

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

4 results found

Lot Number	Certificate Type	Date	Item
K2209328	Certificate of Analysis	Jun 28, 2022	B413622
K2209329	Certificate of Analysis	Jun 28, 2022	B413622
K2209362	Certificate of Analysis	Jun 28, 2022	B413622
K2209366	Certificate of Analysis	Jun 28, 2022	B413622

Chemical and Physical Properties

Solubility	Solubility (25°C) In vitro DMSO: 85 mg/mL (200.29 mM); Ethanol: 2.5 mg/mL (5.89 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility	85
DMSO(mM) Max Solubility	200.292190960931
Water(mg / mL) Max Solubility	＜1

References

1. Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B et al.. (2018) Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.. Cell, 175 (6): (1665-1678.e18). [PMID:30343896]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.